Financials in USD. Standardized financial statements.
A compact view of how Telix Pharmaceuticals Limited turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $1.21B | $783.21M | $502.55M | $160.10M | $7.60M | $5.21M | $3.48M | $195,142 | $0 | $0 |
| Revenue Growth? | +53.9% | +55.8% | +213.9% | +2007.6% | +45.7% | +49.6% | +1685.9% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $565.20M | $273.53M | $188.16M | $65.17M | $38.68M | $2.02M | $15.36M | $0 | $3,793 | $0 |
| Gross Profit? | $640.23M | $509.68M | $314.39M | $94.93M | $5.05M | $3.19M | -$11.88M | $195,142 | -$3,793 | $0 |
| Gross Margin? | +53.1% | +65.1% | +62.6% | +59.3% | +66.5% | +61.2% | -340.7% | +100.0% | 0.0% | 0.0% |
| Operating Expenses? | $613.59M | $427.55M | $263.27M | $186.86M | $53.30M | $29.05M | $28.38M | $27.85M | $6.52M | $30,000 |
| Operating Income? | $26.64M | $82.13M | $15.84M | -$91.93M | -$81.25M | -$44.19M | -$36.02M | -$29.30M | -$6.52M | -$30,000 |
| EBITDA? | $79.83M | $98.23M | $22.97M | -$92.84M | -$70.07M | -$44.94M | -$24.48M | -$27.64M | -$6.77M | -$14,000 |
| Income Before Tax | -$7.90M | $56.06M | $3.09M | -$98.62M | -$99.04M | -$60.25M | -$31.12M | -$15.71M | -$6.38M | -$44,000 |
| Income Tax Expense | $2.79M | $6.14M | -$2.07M | $5.46M | -$18.53M | -$15.37M | -$3.25M | -$1.88M | $0 | $0 |
| Net Income? | -$10.69M | $49.92M | $5.21M | -$104.08M | -$80.51M | -$44.89M | -$27.87M | -$13.83M | -$6.38M | -$44,000 |
| EPS? | $-0.03 | $0.15 | $0.02 | $-0.34 | $-0.29 | $-0.17 | $-0.12 | $-0.07 | $-0.05 | $-0.00 |
| Diluted EPS? | $-0.03 | $0.14 | $0.02 | $-0.34 | $-0.29 | $-0.17 | $-0.12 | $-0.07 | $-0.05 | $-0.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality